Case Study

Managing Risks In The Development And Manufacture Of Potent Pharmaceuticals Products

Clean Room

Due to perceived and real risks, certain classes of pharmaceutical products have historically been manufactured in dedicated or segregated, self-contained facilities, in order to mitigate cross-contamination concerns.  Recent market reports suggest there’s an increasing number of niche and orphan drugs in development, rendering dedicated production facilities less practical.  Given the variety of products currently in development, including potent drugs, outsourcing the development and manufacturing to a CDMO experienced in handling a range of products, in a multi-use facility, has proven to be an effective strategy.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Pharmaceutics International